{"id":"W2950944873","doi":"10.1097/01.hs9.0000563756.72895.a3","title":"PS1370 ELOTUZUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY RESULTS AFTER ADDITIONAL FOLLOW‐UP OF THE PHASE 2, RANDOMIZED ELOQUENT‐3 STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Pomalidomide; Lenalidomide; Medicine; Internal medicine; Dexamethasone; Oncology; Multiple myeloma; Combination therapy; Ixazomib; Refractory (planetary science); Progression-free survival; Bortezomib; Overall survival; Carfilzomib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007231886,0.0003560147,0.001107327,0.00007003103,0.0001337552,0.00002803131,0.0001710411,0.0001542683,0.002315227],"category_scores_gemma":[0.002949822,0.0002244146,0.0004791973,0.0002175069,0.0002382337,0.0001172801,0.0001394575,0.0002909593,0.00006878858],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001841027,"about_ca_system_score_gemma":0.0003392959,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001496387,"about_ca_topic_score_gemma":0.0001051376,"domain_scores_codex":[0.9970077,0.0003896262,0.0007398404,0.0006314882,0.0007323264,0.0004990094],"domain_scores_gemma":[0.9946086,0.003738374,0.0003066109,0.0008057432,0.0002610417,0.0002796034],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9584505,0.005636859,0.01093331,0.0003621524,0.002246628,0.0001517647,0.002033594,0.000008059997,0.001531607,0.00007913051,0.007139792,0.0114266],"study_design_scores_gemma":[0.9449973,0.002103023,0.04353227,0.0003995376,0.0005126579,0.00004338532,0.001018168,0.001027895,0.001467883,0.00005077542,0.004586548,0.0002605917],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9865555,0.0009755156,0.00004688995,0.0002078472,0.0002535142,0.008808246,0.00157997,0.00005031444,0.001522179],"genre_scores_gemma":[0.9860076,0.00002853341,0.001784904,0.0000787795,0.0001111356,0.001441786,0.0004535557,0.00006202002,0.01003163],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03259896,"threshold_uncertainty_score":0.9985968,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02534817731838447,"score_gpt":0.3125158143310527,"score_spread":0.2871676370126683,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}